What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn’s Disease treated with vedolizumab?
Background: Progressive multifocal leukoencephalopathy is a serious condition linked to certain diseases and immunosuppressant therapies, including the α4 integrin antagonist natalizumab. No cases have been reported to date with vedolizumab, a selective antagonist of the α4β7 integrin expressed on g...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Lippincott, Williams & Wilkins
2018
|
| Online Access: | http://eprints.nottingham.ac.uk/48172/ http://eprints.nottingham.ac.uk/48172/ http://eprints.nottingham.ac.uk/48172/ http://eprints.nottingham.ac.uk/48172/1/171004%20PML%20proof%20IBD%20%28002%29.pdf |